Costeffectiveness of Remdesivir and Dexamethasone for COVID19 Treatment in South Africa

dc.citation.doiDOI: 10.1093/OFID/OFAB040
dc.citation.epage8
dc.citation.spage1
dc.contributor.authorYoungji Jo
dc.contributor.authorLise Jamieson
dc.contributor.authorIjeoma Edoka
dc.contributor.authorLawrence Long
dc.contributor.authorS Silal
dc.contributor.authorJ Pulliam
dc.contributor.authorH Moultrie
dc.contributor.authorIan Sanne
dc.contributor.authorGesine Meyer-Rath
dc.contributor.authorBrooke Nichols
dc.date.accessioned2023-04-13T10:25:14Z
dc.date.available2023-04-13T10:25:14Z
dc.identifier.citationWOS
dc.identifier.issn2328-8957
dc.identifier.urihttps://hdl.handle.net/10539/35026
dc.journal.titleOPEN FORUM INFECTIOUS DISEASES
dc.journal.volume8
dc.titleCosteffectiveness of Remdesivir and Dexamethasone for COVID19 Treatment in South Africa
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Journal.pdf
Size:
505.62 KB
Format:
Adobe Portable Document Format
Description:
Journal